Show simple item record

dc.contributor.authorCOVID-19 Evidence Review Group
dc.contributor.authorNational Centre for Pharmacoeconomics
dc.contributor.authorMedicines Management Programme
dc.date.accessioned2020-07-27T15:49:05Z
dc.date.available2020-04-14T12:13:30Z
dc.date.available2020-07-27T15:49:05Z
dc.date.issued2020-06-26
dc.identifier.urihttp://hdl.handle.net/10147/627494
dc.descriptionIn one clinical study, hydroxychloroquine was initiated in hospitalised patients with confirmed COVID-19 at a dose of 200mg three times daily for ten days. The mean time between onset of symptoms and study inclusion was 4.1 days in the treatment group. Not all patients were symptomatic at the time of treatment initiation. A higher rate of virological cure was observed in the hydroxychloroquine-treated group compared with a control group (1). An abstract of a Chinese study suggested no difference in viral clearance between hydroxychloroquine-treated patients and a control group, though patient numbers and effect sizes in this study are too small to robustly determine a difference in efficacy between treatment groups. Insufficient information is available to critically appraise the quality of the study (2). International Guidelines At the time of writing, hydroxychloroquine is more readily accessible than chloroquine in Ireland (3). Hydroxychloroquine is widely recommended in European guidelines for the treatment of patients with COVID-19. Chloroquine is recommended in Chinese guidelines. Guidelines vary in their recommendations to use chloroquine/hydroxychloroquine alone or in combination with other antivirals. Italian and Chinese guidelines recommend combination use and Belgium recommends single-agent use (though this is largely due to uncertainty in the efficacy of other antivirals). These drugs are recommended in mild, moderate and severe disease among the various guidelines. Dose regimens, treatment durations and recommended time of initiation vary across guidelines. Treatment duration varies from 5 days up to 20 days. Use in hospitalised patients is recommended in Belgium, whereas patients with mild symptoms, albeit with risk factors, are recommended treatment in Italy, suggesting a role in primary care.en_US
dc.language.isoenen_US
dc.publisherHealth Service Executiveen_US
dc.relation.ispartofseriesRapid Evidence Reviewen_US
dc.subjectCOVID-19en_US
dc.subjectCORONAVIRUSen_US
dc.subjectANTIVIRAL TREATMENTSen_US
dc.titleClinical evidence for the use of antivirals in the treatment of COVID-19 [v10.0]en_US
dc.typeReporten_US
dc.contributor.departmentHealth Service Executiveen_US
refterms.dateFOA2020-04-14T12:13:30Z


Files in this item

Thumbnail
Name:
clinical-evidence-for-the-use- ...
Size:
484.8Kb
Format:
PDF
Thumbnail
Name:
Antivirals-for-treatment-of-CO ...
Size:
815.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record